Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cardiovascular diseases
3.2.1.2 Advancements in drug development
3.2.1.3 Growing geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with lipid regulators
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Statins
5.2.1 Branded statins
5.2.2 Statin combination
5.2.3 Generic statins
5.3 Non-statins
5.3.1 Fibric-acid derivatives
5.3.2 Bile-acid sequestrants
5.3.3 Ezetimibe
5.3.4 Nicotinic acid derivatives
5.3.5 PCSK9 inhibitors
5.3.6 Other non-statins
Chapter 6 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hypercholesterolemia
6.3 Hypertriglyceridemia
6.4 Coronary artery disease
6.5 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc
10.2 Amgen Inc.
10.3 AstraZeneca plc
10.4 Bristol-Myers Squibb
10.5 Dr. Reddy's Laboratories Ltd.
10.6 Merck & Co.
10.7 Novartis AG
10.8 Pfizer, Inc.
10.9 Sanofi
10.10 Teva Pharmaceuticals
